Suraksha Diagnostic releases Q4FY26 earnings call audio for investor review
Suraksha Diagnostic Limited released the audio recording of its earnings call held on August 13, 2026. The call discussed unaudited standalone and consolidated financial results for Q4FY26. The disclosure complies with SEBI LODR Regulations 30(6) and 46(2).

*this image is generated using AI for illustrative purposes only.
Suraksha Diagnostic has released the audio recording of its earnings call held on August 13, 2026, at 11:30 am. The session addressed the company's unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q4FY26), as well as broader business discussions.
The recording is accessible via the company's official website, fulfilling regulatory disclosure requirements under SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
Regulatory Disclosure
The intimation was issued pursuant to Regulation 30(6) and Regulation 46(2) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. These regulations mandate timely disclosure of material information to stock exchanges to ensure equal access to investors.
Ritu Mittal, Joint Managing Director & CEO, signed the communication. The filing was directed to the secretaries of both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).
Key Details
- Event: Earnings Call Audio Recording Release
- Date of Call: August 13, 2026
- Time: 11:30 am
- Financial Period Covered: Quarter ended June 30, 2026 (Q4FY26)
- Results Type: Unaudited Standalone and Consolidated
- Signatory: Ritu Mittal (Joint Managing Director & CEO)
The release ensures that institutional investors, analysts, and retail shareholders have access to the management's commentary on the financial performance for the full fiscal year 2026 and the final quarter.
Historical Stock Returns for Suraksha Diagnostic
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.22% | +0.25% | +34.68% | +27.31% | +12.52% | 0.0% |
How will Suraksha Diagnostic's Q4FY26 performance influence its valuation multiples compared to key competitors in the Indian diagnostic sector?
What specific growth initiatives or capital expenditure plans did management outline for FY27 during the earnings call?
Are there any indications of margin pressure or expansion in the diagnostic services segment based on the management's commentary?


































